AXSOME Third Quarter 2026 Financial Results - AXSOME THERAPEUTICS INC

Explicit Guidance:

• Revenue Peak: Management expects Avelity (Axon's primary asset) to generate at least $8 billion in annual revenue at peak.
• Gross Margin: Anticipated to remain in the low to mid-90% range with no specific percentage change guidance provided for future quarters beyond typical seasonality.
• Cash Flow & Solvency: Current cash balance of $314 million is deemed sufficient to fund operations until the company achieves cash flow positivity (no specific date provided).
• Gross-to-Net (Discounts):
  • Q4 2026: Expect a slight increase in gross net discounts for both Avelity and Sembravo due to accruals for scripts adjudicating in Q1 2027.
  • Full Year 2027: Anticipate Avelity gross net discounts to be similar to 2026, hovering in the low 50% range, potentially ticking slightly up from the Q3 mid-to-high 40% range.
• Segment Revenue: No specific numerical guidance provided for Q4 2026 or FY 2027 total revenue; management expects "continued growth" but explicitly stated they do not give quarterly or annual guidance.

Business-Segment Outlook:

• Avelity (MDD & Alzheimer's Agitation):
  • Growth Trajectory: Expect sustained momentum in new patient initiations (NBRx) for both MDD and Alzheimer's agitation, with NBRx for patients 65+ growing 211% YoY in Q3; trend expected to convert to Total Rx (TRx) growth in coming quarters.
  • Adoption: Primary care remains the fastest-growing prescriber segment, representing nearly 40% of prescribers; continued expansion expected in this channel for both indications.
  • Long-Term Care (LTC): LTC channel performing well with growth rates similar to the 65+ population; expected to be an important source of business moving forward despite longer sales cycles.
  • Market Dynamics: Sales team expansion (up 49% vs. prior quarter in new prescribers) is driving adoption; expected to mature as the team becomes more productive.
• Sembravo (Migraine):
  • Growth: Exceeded market growth rates (growing 382% YoY in Q3); expected to continue outperforming the broader migraine market.
  • Adoption: Increasing usage among patients with inadequate response to prior acute treatments; coverage expected to expand and evolve in both commercial and government channels.
• Synosy (EDS/Narcolepsy):
  • Growth: Maintaining durable growth (15% YoY, 6% sequential); expected to continue driving demand.
• Pipeline Commercialization:
  • AXS-12 (Narcolepsy): PDUFA date set for May 1, 2027; if approved, intended to differentiate the sleep franchise with a new treatment option for cataplexy.
  • AXS-20 (Schizophrenia): Pivotal Phase 3 trial initiation expected in first half of 2027; first-line therapy positioning; potential to address unmet needs regarding metabolic side effects.
  • Solriamfetol (Label Expansion):
    • ADHD: Top-line results for Focus 2 & 3 (pediatrics/adolescents) anticipated in second half of 2027; NDA filing contingent on positive results.
    • Binge Eating Disorder (BED): Top-line results for ENGAGE trial anticipated in first quarter of 2027.
    • Shift Work Disorder: Top-line results anticipated in second half of 2027.
    • MDD with Excessive Daytime Sleepiness: Enrollment completion anticipated in first half of 2027.

Market and Competitive Outlook:

• MDD & Alzheimer's Agitation: Market described as "new and developing" with significant education required; early days of launch involve overcoming barriers to entry and gaining provider comfort.
• Migraine: Expectation of increased treatment options in a heterogeneous market with inconsistent responses to existing therapies; Sembravo positioned for patients with inadequate response to prior options.
• Narcolepsy: Market viewed as having inconsistent clinical responses to current medications; AXS-12 expected to fill a gap for cataplexy treatment.
• Schizophrenia: Anticipated rising placebo rates in trials; company plans to employ proprietary trial design "bells and whistles" to mitigate this risk.

Macro / Industry Outlook:

• Reimbursement & Access:
  • Medicare Advantage: No anticipated disruption from recent plan closures; patient access and fill rates remain high with manageable co-pays.
  • Formulary Management: No major barriers observed; focus on evolving coverage in both commercial and government channels.
  • Data Reporting: Acknowledged potential fluctuations in third-party script capture rates (IQVIA/Bloomberg) due to pharmacy reporting changes, but notes this does not reflect underlying business performance.
• Supply Chain: No major bottlenecks identified; EMR/e-prescribing updates completed for launch phases.

Strategic Initiatives:

• Pipeline Expansion:
  • AXS-05: Phase 3 trial for smoking cessation initiated in August; top-line results expected in second half of 2027.
  • AXS-14 (Fibromyalgia): Enrollment completion expected in third quarter of 2027; NDA filing anticipated ~6 months after top-line results.
  • AXS-17 (Epilepsy): Clinical trials planned for initiation in first half of 2027.
• Acquisitions/R&D: Completed transactions for schizophrenia (AXS-20) and epilepsy (AXS-17) assets; management confirms these do not impact the investment strategy for driving Avelity growth.
• Sales Force: Expansion is now reflected in the run rate; focus shifting to productivity and effectiveness of the current field force.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: All pipeline milestones (ADHD, BED, Smoking Cessation, Fibromyalgia, Schizophrenia, Epilepsy) are contingent on successful trial results and FDA approvals.
• Trial Design Risks: Potential for rising placebo rates in psychiatric trials (specifically schizophrenia and MDD) could impact clinical outcomes.
• Market Education: Continued need for extensive education on agitation symptoms and product profiles in a new market could delay adoption rates.
• Seasonality: Gross-to-net discounts expected to tick up slightly in Q4 due to accounting accruals for Q1 adjudications.
• Data Variance: Third-party data capture rates (e.g., IQVIA) may fluctuate due to external reporting changes, potentially affecting short-term visibility.

Management Tone on the Future:

• Confidence Level: High. Management described the quarter as "robust" and the business as "well-positioned" with "substantial further growth."
• Key Hedges: Repeatedly noted that specific quarterly/annual guidance is not provided, emphasizing reliance on "continued growth" and "momentum" rather than hard numbers.
• Strategic Focus: Strong emphasis on translating new patient initiations (NBRx) into total prescription volume (TRx) as the sales force matures; confident in the long-term value of the neuroscience pipeline.
• Operational Leverage: Highlighting that revenue growth is increasingly translating to the bottom line (net loss decreased YoY).

Miscellaneous:

• Timing Clarification: Management clarified that enrollment completion in clinical trials does not guarantee immediate top-line results due to the nature of randomized/withdrawal studies (e.g., waiting for pre-specified relapse numbers).
• Investment Strategy: Reaffirmed that recent M&A deals (schizophrenia/epilepsy) are intended to be developed within the pipeline without diverting resources from the core Avelity commercial strategy.